SLIDE 1
Prevention KPIs: The impact of prescribing patterns
2
Confidential property of Optum. Do not distribute or reproduce without express permission from Optum.
Domain 1: Prevention Key Performance Indicators Prevention KPIs: - - PowerPoint PPT Presentation
Domain 1: Prevention Key Performance Indicators Prevention KPIs: - - PowerPoint PPT Presentation
Domain 1: Prevention Key Performance Indicators Prevention KPIs: The impact of prescribing patterns 2 Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. Measuring compliance with the CDC
SLIDE 2
SLIDE 3
Measuring compliance with the CDC prescribing guidelines (2016)
Confidential property of Optum. Do not distribute or reproduce without express permission from Optum.
3
55.4%
Initial opioid prescription compliant with CDC recommendations
100%
Initial prescription is not for methadone
99.6%
Initial opioid prescription is for short acting formulation
77.2%
Initial opioid prescription is for <50MME/day
79.7%
Initial opioid prescription is for <=7 days supply
78.0%
No concurrent opioid and benzodiazepine use
OUTCOME MEASURE PROCESS MEASURES
SLIDE 4
North Carolina: Initial opioid Rx is compliant with CDC recommendations, by county, 2016
(blue = better performance)
4
SLIDE 5
North Carolina: Initial opioid Rx is for < 50 MME/day, by county, 2016
(blue = better performance)
5
SLIDE 6
North Carolina: Initial opioid Rx is for < 7 days’ supply, by county, 2016
(blue = better performance)
6
SLIDE 7
Additional prescribing indicators (2016)
Confidential property of Optum. Do not distribute or reproduce without express permission from Optum.
7
87.1% 78.0% 54.0%
No use of opioids for new low back pain patients No concurrent opioid and benzodiazepine use Appropriate contact with provider before second opioid prescription
122
97.9%
35.9
New opioid fillers per 1,000 enrollees New opioid fillers who avoid chronic use Prevalence of opioid
- verdose (OD) per 100,000
person-years
OUTCOME MEASURES PROCESS MEASURES
SLIDE 8